Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8657492 | 0.95 | KDM4E (0.43) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL14431663 | 0.86 | KDM4E (0.38) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL1469433 | 0.85 | TAAR1 (0.46) | KDM4ETDP1IDO1CYP11B1CYP11B2 | |
| SCHEMBL332715 | 0.84 | KDM4E (0.37) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL1072135 | 0.84 | KDM4E (0.41) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL25170271 | 0.84 | CA12 (0.48) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL25808872 | 0.84 | KDM4E (0.37) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL1401399 | 0.84 | CYP4F2 (0.41) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL20576683 | 0.84 | KDM4E (0.37) | KDM4ETDP1IDO1ENPP2CYP11B1 | |
| SCHEMBL25990556 | 0.84 | KDM4E (0.37) | KDM4ETDP1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| CN-120184379-A | Flame-retardant electrolyte and preparation method thereof | 抚顺国腾润滑科技有限公司 | 2025-06-20 | — | — | CN | disclosed |
| WO-2025104443-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| CN-119874565-A | Mono cyano diaryl ethylene preparation method of class compound | 常州大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-116854668-B | Phthalazinone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-115677731-B | Organic compound and application thereof in organic electronic device | 广州追光科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240004296-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0787127-B1 | 5-LIPOXYGENASE INHIBITORS | PFIZER (US) | 2001-01-03 | — | — | EP | disclosed |
| CN-1253554-A | Heterocyclic compounds and their use for inhibiting 'beta'-amyloid peptide | ELAN MEDICINE CO (US) | 2000-05-17 | — | — | CN | disclosed |
| US-6063928-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, CARDIOTONIC AGENTS | PFIZER INC (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0968198-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE | Elan Pharmaceuticals, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5883106-A | 5-lipoxygenase inhibitors | PFIZER INC. (US) | 1999-03-16 | — | — | US | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| EP-0787127-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996011911-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| CN-1119099-A | Method for preparing pharmacologically active CNS composition | WELLCOME FOUND (GB) | 1996-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | KDM4E 3052/4885TDP1 3142/4885IDO1 4206/4885 |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | KDM4E 3489/4885TDP1 2286/4885IDO1 2668/4885 |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | KDM4E 1780/4885TDP1 2368/4885IDO1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.